source
- Oruka posts Phase 2 win in psoriasis, hoping to compete with SkyriziOruka Therapeutics' Phase 2 psoriasis data could mean there's a future challenger to megablockbuster Skyrizi. The company said on Monday that 40 of 63 patients (63.5%) who took an experimental drug…Endpoints · 3mo ago↗ source
- STAT+: Astellas retries XLMTM gene therapy after deathsVeradermics' hair loss pill late-stage trial success, FDA fast-tracks reviews for psychedelics, and more biotech newsSTAT · 3mo ago↗ source
- STAT+: Pharmalittle: We’re reading about a Lilly deal, an Intellia CRISPR rare-disease treatment, and moreIntellia disclosed that a single dose of its gene editing treatment dramatically reduced swelling attacks in patients with hereditary angioedemaSTAT · 3mo ago